The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective

BACKGROUND: The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: van Asten, Freekje, Michels, Charlotte T. J., Hoyng, Carel B., van der Wilt, Gert Jan, Klevering, B. Jeroen, Rovers, Maroeska M., Grutters, Janneke P. C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5957378/
https://ncbi.nlm.nih.gov/pubmed/29772018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0197670
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares